Monitor upcoming clinical catalysts: ELEVATE-44-201 Cohort 1 open-label data by year-end 2026, Cohort 2 data in Q1 2027, and Vertex's VX-670 interim results in H2 2026. Cash runway into Q4 2027 provides sufficient funding through these readouts.
Price Chart
Executive Summary
The company highlighted positive safety data from ELEVATE-45-201 Cohort 1 and progress across its DMD clinical pipeline, with multiple data readouts expected through H1 2027.
Key Financial Metrics
Key Facts
- Net loss of $39.7 million for Q3 2026, compared to $44.1 million in Q3 2025
- Cash, cash equivalents and marketable securities of $193.0 million as of September 30, 2026
- Cash runway extended into Q4 2027
- Collaboration revenue of $0.9 million for Q3 2026, down from $1.6 million in Q3 2025
- R&D expenses decreased to $32.4 million from $38.4 million year-over-year
- ELEVATE-45-201 Cohort 1 data met primary safety and tolerability objectives in October 2026
- FDA granted orphan drug designation for ENTR-601-45 for DMD treatment
- DMC recommended initiating ELEVATE-44-201 Cohort 3 at highest planned dose (18 mg/kg)
- Vertex on track to share interim VX-670 GALILEO study results in H2 2026
Financial Impact
Net loss improved by $4.4M YoY; cash burn of $102.7M over nine months; cash runway extended by one quarter vs prior guidance
Risk Factors
- Clinical-stage biotech with no approved products and recurring net losses
- Cash burn rate of ~$34M per quarter may require future financing
- Dependence on positive clinical data from multiple ongoing DMD trials
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001689375-26-000063 |
| Document: trda-20261105.htm | 0001689375-26-000063 |
| Document: 0001689375-26-000063-index-headers.html | 0001689375-26-000063 |
| Document: 0001689375-26-000063-index.html | 0001689375-26-000063 |
| Document: 0001689375-26-000063.txt | 0001689375-26-000063 |
| 8-K Data (Synthetic) | 0001689375-26-000063 |
Track record
21 reports on TRDA
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +58.22% at T+20 after the May 4, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 5, 202611d ago 8-K Neutral 4/10 Viewing No price data
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $4.55 Now $5.00 +9.89% settles Feb 3
- Oct 14, 20264w ago 8-K Bullish 6/10 Entry $4.55 Now $5.00 +9.89% settles Jan 11
- Sep 9, 20269w ago Insider Cluster Bearish 6/10 Entry $6.42 Now $5.00 +22.12% settles Dec 4
- Sep 3, 202610w ago Insider Cluster Neutral 3/10 Entry $7.13 Now $5.00 −29.87% settles Dec 1
- Aug 31, 202611w ago Insider Cluster Neutral 4/10 Entry $7.07 Now $5.00 −29.28% settles Nov 25
- Aug 31, 202611w ago Insider Cluster Neutral 4/10 Entry $7.07 Now $5.00 −29.28% settles Nov 25
- Aug 31, 202611w ago Insider Cluster Neutral 3/10 Entry $7.07 Now $5.00 −29.28% settles Nov 25
- Aug 26, 202611w ago Insider Cluster Neutral 3/10 Entry $7.27 Now $5.00 −31.22% settles Nov 20
- Aug 10, 202614w ago Insider Cluster Neutral 2/10 Entry $7.04 to $5.06 Now $5.00 −28.98% ▼ −28.13% −27.64% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers